Clinical trials
High Bleeding Risk clinical trials
Below are recruiting high bleeding risk clinical trials, each written for real people, not researchers. We’re tracking 143 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07149714Recruiting
Heart pump support for high-risk angioplasty
This trial tests the iVAC 2L device, a temporary heart pump placed in the main artery, to help patients who need a high-risk angioplasty (PCI) because of a very narrowed or blocked coronary artery. The goal is to prevent the heart from failing during the procedure.
MoscowAges 18 years+ - NCT07151885Recruiting
Using ultrasound and blood tests to predict varices risk in cirrhosis
This trial tests if a special ultrasound technique combined with liver stiffness and platelet count can predict which patients with cirrhosis have high-risk varices in the esophagus or stomach, potentially reducing the need for repeated endoscopy.
Changchun, JilinAges 18 years+ - NCT07122622Recruiting
Spleen stiffness test to check for dangerous veins in the liver
This trial uses a non-invasive ultrasound test to measure spleen stiffness, which may help find problems with blood pressure in the liver and identify enlarged veins that can bleed. It could help avoid more invasive tests.
Roma, ItaliaAges 18 years+ - NCT06967038RecruitingPhase 1/Phase 2
Natural killer cell therapy for high-risk lymphoma with Sjogren's syndrome
This trial tests a new type of immune cell therapy using natural killer cells to treat people who have both high-risk lymphoma and primary Sjogren's syndrome. The goal is to see if these cells can safely and effectively fight the lymphoma while managing the autoimmune condition.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT07064681Recruiting
AK104 plus TACE for resectable liver cancer
This trial tests whether adding an immunotherapy drug (AK104) to a standard liver cancer treatment (TACE) helps prevent the cancer from coming back after surgery. It is for people with early-stage liver cancer that can be surgically removed and who have a high risk of recurrence.
Guangzhou, GuangdongAges 18–75 - NCT07036731Recruiting
Urine test study for second bladder surgery
This trial compares the need for a second surgery for people with early-stage bladder cancer. It uses a simple urine test to see if the test can help decide whether a second operation is necessary, which could save some patients from an extra procedure.
Nanjing, JiangsuAges 18–80 - NCT07019623Recruiting
U-CaVIT device vs standard care for preventing heavy bleeding after c-section
This study tests a new device called U-CaVIT to prevent heavy bleeding after a planned cesarean delivery in women at high risk. It compares the U-CaVIT device to standard care to see which works better.
ZurichAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Phoenix, ArizonaAges 18 years+ - NCT06826859RecruitingPhase 1/Phase 2
Daily aspirin vs split dosing to prevent preeclampsia
This study compares taking a daily low-dose aspirin (a single pill) versus splitting the same dose into two smaller pills many hours apart to see which way better prevents preeclampsia in pregnant people who are at higher risk.
Philadelphia, PennsylvaniaAges 16–55 - NCT06822010RecruitingPhase 2
Gemcitabine and Mitomycin for High-Risk Upper Tract Cancer
This trial tests a combination of two chemotherapy drugs, gemcitabine and mitomycin, given directly into the kidney or ureter through a thin tube. It is for people with a high-risk but non-invasive form of upper urinary tract cancer that has not spread into deeper tissues.
New Brunswick, New JerseyAges 18–99 - NCT06798558RecruitingPhase 2
Lu-PSMA before prostate surgery for high-risk cancer
This trial tests a treatment called Lu-177-PSMA-617 given before surgery for high-risk prostate cancer that has spread only to nearby lymph nodes. It aims to see if this approach helps control the cancer before the prostate is removed.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05984537RecruitingPhase 4
Bivalirudin during angioplasty for high-risk heart plaques
This study tests whether a blood thinner called bivalirudin, given during a procedure to open blocked heart arteries (PCI), helps blood flow better in the tiny vessels of the heart afterward. It is for people with a recent unstable heart condition and a high-risk plaque seen on a CT scan.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06682728RecruitingPhase 2
Treating high-risk bladder cancer after surgery
This trial tests a combination of two drugs (sacituzumab govitecan and nivolumab) given after surgery to prevent the return of muscle-invasive bladder cancer. It is for patients whose cancer has a high chance of coming back despite surgery.
Orange, CaliforniaAges 18 years+ - NCT06672081Recruiting
Early catheter treatment for high-risk pulmonary embolism
This study tests whether using a catheter (a thin tube) to remove blood clots from the lungs early can help people with a severe, life-threatening pulmonary embolism. It is for patients who are in shock or have had a cardiac arrest due to a large clot.
Bad KrozingenAges 18 years+ - NCT06660186Recruiting
Sternal plating for high-risk heart surgery patients
This study looks at whether using special metal plates to close the breastbone after heart surgery can help people at higher risk for slow healing. It may be an option if you have multiple risk factors like diabetes, heavy smoking related lung disease, or obesity.
Cleveland, OhioAges 18–89 - NCT06453876RecruitingPhase 3
Comparing clot removal, low-dose clot dissolver, and heparin for high-risk lung clot
This trial compares three treatments for an intermediate-high risk pulmonary embolism: a minimally invasive clot removal procedure (embolectomy), a low-dose clot-dissolving medication, or standard blood thinning (heparin). The goal is to see which approach works best to prevent worsening while reducing bleeding risks.
CopenhagenAges 18 years+ - NCT06440850RecruitingPhase 2
Targeted therapy for high-risk BRAF-mutated thyroid cancer
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Duarte, CaliforniaAges 18 years+ - NCT06362746RecruitingPhase 3
Staphylokinase for intermediate high-risk pulmonary embolism
This trial tests a new drug, staphylokinase, to see if it can break up blood clots in the lungs in people with a moderate-high risk pulmonary embolism. The goal is to improve blood flow and reduce the chance of complications.
Barnaul, Altayskiy KrayAges 18 years+ - NCT06295497Recruiting
Lung cancer screening for non-smokers with a family history
This study tests an artificial intelligence device to screen for lung cancer in people who have never smoked but have a close family member with lung cancer. If you are between 50 and 75 and fit for possible surgery, you may be able to join.
Hong KongAges 50–75 - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT06207799RecruitingPhase 2
Drug combo before and after transplant for high-risk myeloma
This trial tests a two-step approach for people with newly diagnosed, high-risk multiple myeloma who are eligible for a stem cell transplant. You'll get a drug called elranatamab before transplant to 'purge' the cancer, and then after transplant, you'll get maintenance therapy guided by how well your cancer is controlled. The goal is to see if this reduces the chance of the cancer coming back.
Houston, TexasAges 18–75 - NCT06210490RecruitingPhase 2
Antibody-drug combo with radiation for HER2+ UTUC after surgery
This trial tests a combination of an antibody-drug conjugate (Disitamab Vedotin) plus radiation therapy after surgery to prevent upper tract urothelial cancer from coming back. It is for patients with HER2-positive tumors and high-risk features who cannot receive cisplatin chemo.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06143969Recruiting
Ultrasound-guided clot-dissolving treatment for intermediate-high risk pulmonary embolism
This trial tests a treatment that uses ultrasound to guide a thin tube (catheter) to deliver clot-busting medicine directly into the blood clot in your lung. It may be an option for people whose clot is serious but not yet causing shock, and who have symptoms that started within the last two weeks.
Milan, ItaliaAges 18 years+
Hear when a new High Bleeding Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high bleeding risk?
- Yes. Clin2 currently lists 143 recruiting high bleeding risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high bleeding risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high bleeding risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.